| Justin Matthew Fetsko, DPT | |
|
348 Healthwest Dr, Dothan, AL 36303-1907 | |
| (334) 699-5747 | |
| Not Available |
| Full Name | Justin Matthew Fetsko |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 16 Years |
| Location | 348 Healthwest Dr, Dothan, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174843130 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PTH5315 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dothan Therapy Associates Inc | 5799731972 | 6 |
News Archive
Researchers have developed a 3D polymer sponge that absorbs excess chemotherapy drugs from the bloodstream following treatment.
On a conference call with reporters Tuesday, Karen Ignagni, president and CEO of America's Health Insurance Plans, said the "Washington politics of 'find an enemy and go to war' is a major step backward," damaging the possibility of building consensus on health reform.
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
Teleflex Incorporated today announced financial results for the second quarter and six months ended June 26, 2011.
› Verified 9 days ago
| Provider Name | Dothan Therapy Associates Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477647816 PECOS PAC ID: 5799731972 Enrollment ID: O20050330001042 |
News Archive
Researchers have developed a 3D polymer sponge that absorbs excess chemotherapy drugs from the bloodstream following treatment.
On a conference call with reporters Tuesday, Karen Ignagni, president and CEO of America's Health Insurance Plans, said the "Washington politics of 'find an enemy and go to war' is a major step backward," damaging the possibility of building consensus on health reform.
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
Teleflex Incorporated today announced financial results for the second quarter and six months ended June 26, 2011.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Justin Matthew Fetsko, DPT 348 Healthwest Dr, Dothan, AL 36303-1907 Ph: (334) 699-5747 | Justin Matthew Fetsko, DPT 348 Healthwest Dr, Dothan, AL 36303-1907 Ph: (334) 699-5747 |
News Archive
Researchers have developed a 3D polymer sponge that absorbs excess chemotherapy drugs from the bloodstream following treatment.
On a conference call with reporters Tuesday, Karen Ignagni, president and CEO of America's Health Insurance Plans, said the "Washington politics of 'find an enemy and go to war' is a major step backward," damaging the possibility of building consensus on health reform.
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
Teleflex Incorporated today announced financial results for the second quarter and six months ended June 26, 2011.
› Verified 9 days ago
Madison Carter Pemberton, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 122 S Woodburn Dr, Dothan, AL 36305 Phone: 334-446-1425 | |
Charles C Outlaw, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3118 Ross Clark Cir, Dothan, AL 36303 Phone: 334-673-2242 Fax: 334-793-8191 | |
Alana Dianne Pearce, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1207 Ross Clark Cir, Dothan, AL 36301 Phone: 334-500-1150 Fax: 334-828-7125 | |
Daniel R Peters, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3160 W Main St, Suite 1, Dothan, AL 36305 Phone: 334-699-2348 Fax: 334-699-2347 | |
Sherra K Shivers, PHYSICAL THERAPY Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1000 W Main St, Suite 460, Dothan, AL 36301 Phone: 334-794-0591 Fax: 334-793-6073 | |
Malcolm Chase Murphy, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 501 N Woodburn Dr, Dothan, AL 36303 Phone: 334-794-1000 | |
Laura Lee Homan, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 345 Healthwest Dr, Dothan, AL 36303 Phone: 334-836-5423 Fax: 334-836-2287 |